Mediclinic International : Intnl plc - Director Declaration

Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

('Mediclinic' or 'the Company')

1 June 2018

DIRECTOR DECLARATION

Mediclinic, a leading international private healthcare services group, confirms that, as announced on 29 March 2018, Dr Ronnie van der Merwe succeeded Mr Danie Meintjes as Chief Executive Officer ('CEO') of the Company with effect from today. Dr Van der Merwe will retain his responsibilities as Group Chief Clinical Officer until a suitable successor has been identified.

In accordance with Listing Rule 9.6.14R(2), the Company further announces that Mediclinic Jersey Limited, an indirect wholly-owned subsidiary of the Company and holder of a 29.9% interest in Spire Healthcare Group plc ('Spire'), has nominated Dr Van der Merwe to be appointed as a non-executive director of Spire from the conclusion of the Spire annual general meeting held on 24 May 2018.

There are no further disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of Dr van der Merwe's appointment as CEO of the Company.

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Jayne Meacham / Caroline Emmet

+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website:www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor:Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor:Simonis Storm Securities (Pty) Ltd